BACKGROUND Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS).
D
espite the significant benefits of antiplatelet therapy for reducing ischemic and thrombotic events in patients with acute coronary syndromes (ACS) (1) (2) (3) , patients remain at high residual risk of repeat cardiovascular events after ACS, which is perhaps in part related to persistent thrombin generation (4) . Consequently, there may be a role for long-term anticoagulants in addition to antiplatelet agents for the treatment of ACS. With respect to efficacy, studies of oral anticoagulation in the ACS population have provided mixed results; although warfarin and low-dose rivaroxaban were found to reduce recurrent ischemic and thrombotic events (5-7), apixaban and dabigatran did not provide any efficacy benefits compared with placebo (8, 9) . In contrast, studies have consistently demonstrated increased bleeding with the addition of anticoagulation to platelet inhibition in patients after an ACS (5, 8) .
Altering concomitant antiplatelet regimens, such as the use of mono rather than dual antiplatelet therapy, may mitigate some of the bleeding risks of novel oral anticoagulants in patients after an ACS, but these changes might also increase ischemic events.
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Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster. Hess et al. BASELINE CHARACTERISTICS. As expected, baseline characteristics between randomized apixaban and placebo groups were well-matched. Therefore, we examined baseline characteristics according to use of aspirin versus aspirin plus clopidogrel. As shown in Table 2 , the largest proportion of patients on aspirin only were enrolled in Eastern Europe, whereas enrollment of patients on aspirin plus clopidogrel was more even across geographic regions. Compared with patients on aspirin alone, patients on aspirin plus clopidogrel were more often male, had a greater burden of comorbidities (including diabetes, previous MI, peripheral artery disease, and previous coronary Values are n (%) or median (25th, 75th percentiles). *Includes 1,202 patients on aspirin alone, 162 patients on clopidogrel alone, 4 patients on prasugrel alone, and 1 patient on ticlopidine alone. †Includes 5,814 patients on aspirin and clopidogrel, 146 patients on aspirin and prasugrel, 23 patients on aspirin and ticlopidine, 9 patients on aspirin, clopidogrel, and prasugrel, and 3 patients on aspirin, clopidogrel, and ticlopidine. Twenty-three not on any antiplatelet therapy at randomization and 5 patients missing information about antiplatelet use were excluded.
ACS ¼ acute coronary syndromes. Table 3 . More than 60% of the composite ischemic endpoint was comprised of MI events, and there were low numbers of ischemic stroke and stent thrombosis in the aspirin only group. Figure 4 shows that similar results were obtained using MSM modeling.
DISCUSSION
Using data from the APPRAISE-2 trial, we found that approximately 20% of patients changed antiplatelet therapy regimen at least once after randomization. Trends in the use of aspirin alone in the main study population as well as in patients treated with and without percutaneous coronary intervention (PCI).
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There was no effect on efficacy and increased bleeding In our study, randomization of patients occurred at a median of 6 days after the index ACS event.
In accordance with ACS treatment guidelines (14) (15) (16) (17) , almost all patients (97%) were on aspirin at baseline. However, 19% of patients were on a single antiplatelet agent at randomization, despite guidelines recommendations for dual antiplatelet therapy for ACS. This might be partially due to regional variation in practice patterns, because the majority of Values are n (%) or median (25th, 75th percentile).
ACE ¼ angiotensin converting enzyme; ACS ¼ acute coronary syndromes; BMI ¼ body mass index; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; other abbreviation as in Table 1. JACC VOL. 66, NO. 7, 2015 Hess et al. Hess et al. Event rates per 100 patient-years of follow-up (number of events in parentheses), adjusted HRs and 95% CIs for patients assigned to apixaban versus placebo among patients taking aspirin alone or aspirin plus clopidogrel. Results from subgroup analyses according to treatment with or without PCI are included. Results among the PCI subgroup for certain outcomes are not available (N/A) due to small event numbers. Figure 3 .
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